Kokuma unveils breakthrough depigmenting lively at SCALE & NYSCC Provider’s Day

Brussels-headquartered biotech startup Kokuma is bringing its novel depigmentation actives to the U.S. market, participating dermatology leaders at SCALE Nashville (Could 13–17) earlier than making its debut at NYSCC Suppliers’ Day in New York (Could 19–20).

Kokuma says its biotech-derived lively, Tonasulike-D — proven to visibly fade spots in 21 days throughout all pores and skin tones — meets rising U.S. demand for clinically backed, well-tolerated alternate options to conventional depigmenting brokers.

“Within the U.S. dermatology and cosmeceutical area, there may be robust demand for clinically supported alternate options to conventional depigmentations brokers corresponding to hydroquinone. Tonasulike-D is especially fascinating as a result of it combines stable scientific knowledge and is straightforward to formulate into premium skincare strains, together with pre- and post-procedure care,” shared Dr. Michael Gold, famend Dermatologist lately appointed as Kokuma’s Scientific Advisor.

On the middle of its U.S. introduction, Tonasulike-D is a patented depigmenting lively designed to visibly scale back hyperpigmentation and enhance total pores and skin tone. Backed by three years of R&D and scientific research, it delivers fast depigmentation and progressive brightening over time.

Scientific analysis throughout pores and skin varieties III–V confirmed constant enhancements in pigmentation and brightness, with seen outcomes from Day 21 and continued progress over 12 weeks. All individuals demonstrated enchancment by week 8. Notably, outcomes confirmed as much as a +24% improve in brightness (ITA) on darker pores and skin tones, reinforcing its relevance for inclusive pigmentation care. These issues stay among the many most typical dermatological situations in the US, notably the place melasma and post-inflammatory hyperpigmentation happens.

Tonasulike-D additionally meets post-procedure care wants with a multi-pathway mechanism—concentrating on melanogenesis and melanosome switch moderately than relying solely on tyrosinase inhibition.

In line with Kokuma, the ingredient is odorless, white, steady, and straightforward to formulate, enabling use throughout facial care, physique care, and pre- and post-procedure skincare.